Adimab Closes Third VC Round

Xconomy Boston — 

Adimab, a Lebanon, NH-based biotech firm focused antibody discovery, says it has closed a Series C round of financing from new investors OrbiMed Advisors, Borealis Ventures, and return backers Polaris Venture Partners and SV Live Sciences. Financial details weren’t disclosed. Tillman Gerngross, CEO and co-founder of the company, said in a statement that his company is able to speed the time required to discover antibodies to a matter of weeks.